Skip to content
Peptigraph home

CJC-1295 + Ipamorelin blend calculator

A two-peptide blend vial: CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin. Work out how much of each peptide is in one draw, from the dose of one peptide or from the units you draw.

Also calledCJC/IpaMod GRF 1-29 + Ipamorelin
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Educational use only
1Vial and what is in it
mg of each peptide. Change them to match your vial label.
mg
mg
2Bacteriostatic water added
mL
3What you know
Calculate from
Peptide to dose by
Dose of Ipamorelin
mcg
4Syringe (U-100)
Draw to
10units
= 0.1 mL on a 1 mL U-100 insulin syringe
Each draw contains
  • CJC-1295 (no DAC)250 mcg50%
  • Ipamorelin250 mcg50%
Vial total
10 mg
Total mg/mL
5
Draws per vial
20
Math only. It does not recommend a dose. Each peptide's share of the draw is fixed by the vial, so you cannot dose one without the others.

CJC-1295 + Ipamorelin: 10 units (0.1 mL) from a 10 mg vial + 2 mL water = 250 mcg CJC-1295 (no DAC), 250 mcg Ipamorelin.

How the blend math works

Each peptide has its own concentration: its milligrams divided by the water you add. Whatever volume you draw, every peptide comes along in proportion. Dosing by one peptide sets the volume, and that volume sets the dose of all the others.

CJC-1295 (no DAC): 5 mg ÷ 2 mL = 2.5 mg/mLIpamorelin: 5 mg ÷ 2 mL = 2.5 mg/mL0.25 mg Ipamorelin ÷ 2.5 mg/mL = 0.1 mL = 10 unitsCJC-1295 (no DAC): 0.1 mL × 2.5 mg/mL = 250 mcgIpamorelin: 0.1 mL × 2.5 mg/mL = 250 mcg
10 units · 250 mcg CJC-1295 (no DAC) · 250 mcg Ipamorelin

What is in a CJC-1295 + Ipamorelin vial

Amount of each peptide per CJC-1295 + Ipamorelin vial
Peptide10 mg vial4 mg vial
CJC-1295 (no DAC)5 mg (50%)2 mg (50%)
Ipamorelin5 mg (50%)2 mg (50%)
These are the typical amounts users report for CJC-1295 + Ipamorelin vials in community discussions (Jan 2025 to Oct 2026), not a verified label. Sellers fill vials differently, so enter the amounts printed on your vial in the calculator.

What each component has in human studies

CJC-1295's human trials gave it subcutaneously, as ascending single doses and then repeated weekly or biweekly doses, against placebo.[3]

In those CJC-1295 trials the main outcome measures were peak concentrations and area under the curve of GH and IGF-I, plus standard pharmacokinetic parameters for CJC-1295.[3]

Ipamorelin's human data are intravenous: its phase 2 trial in bowel-resection patients used infusions rather than injections under the skin.[4]

In that trial the median time to a first tolerated meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a gap that did not reach significance (p = 0.15).[4]

In the healthy-volunteer ipamorelin study the doses were infusions over 15 minutes, not injections under the skin.[5]

That study reported a terminal half-life of 2 hours.[5]

Has anyone tested them together?

A PubMed title/abstract search for CJC-1295 with ipamorelin returned 10 records on 2 Oct 2026, and the dataset classes 0 of them as a study of the pair.

Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab]); search date 2026-10-02; records returned 10; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (key cjc-1295__ipamorelin); no arithmetic applied.

The community-reported vial strengths split evenly: 5 mg of each in the 10 mg vial and 2 mg of each in the 4 mg vial, so each component is 50% of the powder by weight.

Calculated from variants mg 10 mg vial 5, 5, 4 mg vial 2, 2. Formula: 5 / (5 + 5) = 50%; 2 / (2 + 2) = 50%

FDA wording that applies to each ingredient

FDA's safety-risk page for ipamorelin acetate cites immunogenicity risk for certain routes, unnatural amino acids, and serious adverse events including death when it was given intravenously to improve gastric motility.[6]

For CJC-1295, FDA says it has identified serious adverse events including increased heart rate and a systemic vasodilatory reaction.[6]

Common questions

How many units of CJC-1295 + Ipamorelin for 250 mcg of Ipamorelin?

In a 10 mg CJC-1295 + Ipamorelin vial (5 mg CJC-1295 (no DAC), 5 mg Ipamorelin) mixed with 2 mL of water, Ipamorelin is at 2.5 mg/mL, so 250 mcg is 10 units (0.10 mL) on a U-100 syringe. That same draw also contains 250 mcg CJC-1295 (no DAC).

How much of each peptide is in 10 units of CJC-1295 + Ipamorelin?

10 units on a U-100 syringe is 0.10 mL. From a 10 mg CJC-1295 + Ipamorelin vial (5 mg CJC-1295 (no DAC), 5 mg Ipamorelin) with 2 mL of water, that draw holds 250 mcg CJC-1295 (no DAC), 250 mcg Ipamorelin.

Is CJC-1295 with ipamorelin a studied combination?

No. The dataset's PubMed search returned 10 records mentioning both peptides, and none is classed as a study of the combination.

Calculated from records returned 10; classed as study of the pair 0; key cjc-1295__ipamorelin. Formula: Counts copied from the combinations dataset; no arithmetic applied.

What does ipamorelin's human evidence show?

A phase 2 trial in bowel-resection patients found no significant difference from placebo in time to first tolerated meal.[4]

Has FDA flagged safety issues with the ingredients?

Yes: for CJC-1295 it names increased heart rate and a systemic vasodilatory reaction.[6]

Is CJC-1295 without DAC the same as the CJC-1295 in studies?

They are named as separate forms: a review of online peptide use lists CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC as distinct GHRH analogues. The cached abstract of the human CJC-1295 trial does not mention a no-DAC form.[7]

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  4. 4Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  5. 5Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  6. 6Official web pageOfficial web page · web page
  7. 7The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026

Found an error? Report a correction.